bladder cancer

New bladder cancer, kidney disease therapies availableFDA recently approved 2 new therapies: an expanded drug indication for locally advanced or metastatic urothelial carcinoma (mUC) and a treatment for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
Uro Pipeline: FDA accepts biologics license application for bladder Ca agentOther pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
How Sanofi’s discontinuation of BCG affects patients, cliniciansSanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.
Uro Pipeline: Data from mUC combination therapy suggests efficacy, safetyOther pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
Researchers validate robotic cystectomy quality toolA team from Roswell Park Cancer Institute has developed and validated a quality assessment tool based on prospectively collected data on robot-assisted cystectomy.
Uro Pipeline: FDA committee votes in favor of nocturia treatment approvalOther pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
PD-L1 inhibitor shows promise as first-line therapy
PD-L1 inhibitor shows promise as first-line therapyA recently approved treatment for urothelial carcinoma provides durable responses when used as first-line treatment in patients who are ineligible for cisplatin-based therapy, according to a recent study.
Uro Pipeline: Bladder Ca drug-device combination begins second phase Ib trialA bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.
Study data may help risk stratify microhematuria DxA recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.